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Abstract
Accumulation of a-synuclein (a-syn) fibrils in Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson
disease (PD). Ligands that bind a-syn fibrils could be utilized as imaging agents to improve the diagnosis of PD and to
monitor disease progression. However, ligands for a-syn fibrils in PD brain tissue have not been previously identified and
the feasibility of quantifying a-syn fibrils in brain tissue is unknown. We report the identification of the 125I-labeled a-syn
radioligand SIL23. [125I]SIL23 binds a-syn fibrils in postmortem brain tissue from PD patients as well as an a-syn transgenic
mouse model for PD. The density of SIL23 binding sites correlates with the level of fibrillar a-syn in PD brain tissue, and
[125I]SIL23 binding site densities in brain tissue are sufficiently high to enable in vivo imaging with high affinity ligands.
These results identify a SIL23 binding site on a-syn fibrils that is a feasible target for development of an a-syn imaging
agent. The affinity of SIL23 for a-syn and its selectivity for a-syn versus Ab and tau fibrils is not optimal for imaging fibrillar a-
syn in vivo, but we show that SIL23 competitive binding assays can be used to screen additional ligands for suitable affinity
and selectivity, which will accelerate the development of an a-syn imaging agent for PD.
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Introduction
Accumulation of misfolded, fibrillar a-syn in Lewy bodies (LB)
and Lewy neurites (LN) is a definitive marker for the pathological
diagnosis of PD. Pathological a-syn accumulation accompanies the
degeneration of substantia nigra dopaminergic neurons underlying
the motor features of PD, which include tremor, bradykinesia and
rigidity. Approximately 80% of PD patients develop dementia
within 20 years after onset of motor symptoms [1], and the
development of cognitive impairment correlates with neocortical
a-syn accumulation [2–4]. Since the clinical features of PD often
overlap with those of other parkinsonian disorders, such as
multiple system atrophy (MSA), progressive supranuclear palsy
(PSP) and corticobasal degeneration (CBD), an imaging tracer that
detects fibrillar a-syn accumulation could improve diagnostic
accuracy for PD. Furthermore, quantifying the distribution of
pathological a-syn in vivo could improve our understanding of
disease progression, including the onset of dementia in PD
patients. Thus, an imaging biomarker to quantify pathological a-
syn could be valuable to test potential disease-modifying therapies
and to distinguish more homogenous groups for therapeutic trials
and treatment.
a-Syn is a presynaptic protein that normally exists in a natively
unfolded state and is highly soluble [5,6]. In PD, a-syn forms
highly ordered insoluble aggregates called amyloid fibrils, which
are stabilized by beta sheet protein structure [7,8]. Fibrillar
aggregate accumulation also occurs in other neurodegenerative
diseases. Alzheimer’s disease (AD) is defined by accumulation of
both amyloid Ab and tau proteins. Pathological accumulation of
tau but not Ab occurs in a subset of frontotemporal lobar
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dementias [9]. Pittsburgh Compound B (PiB), a derivative of
Thioflavin-T (ThioT), has been highly useful as a positron
emission tomography (PET) probe for selectively quantifying
amyloid Ab in vivo [10]. PiB has high affinity for Ab fibrils and for
pathological Ab in postmortem brain tissue [11]. PiB has also been
reported to bind recombinant a-syn fibrils, but does not bind
pathological a-syn in brain tissue and does not detect LB
pathology when used as a PET probe [12–14]. Additional imaging
ligands for Ab fibrils and for tau fibrils are under development
[15–18], but radioligands which bind fibrillar a-syn in PD brain
tissue have not been previously reported.
We utilized binding studies with recombinant a-syn fibrils and
preparations from postmortem brain tissue to identify and
characterize a radioligand binding site on a-syn fibrils in PD.
These studies are important to determine the feasibility of
targeting a-syn fibrils in vivo for development of an imaging agent,
and to establish methods for developing a-syn imaging ligands
with suitable affinity and selectivity properties.
Methods
Ethics Statement
Because this research project only involved the use of
postmortem tissue, it did not meet the definition of human
subjects research and did not require approval by the Human
Research Protection Office at Washington University in St. Louis.
Written consent for autopsy was obtained from the next of kin at
the time of death.
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal procedures were performed according to protocols
approved by the Washington University Animal Studies Commit-
tee (Protocol Number: 20110018).
General
All reagents were purchased from Sigma-Aldrich (St. Louis,
MO) unless otherwise indicated.
Postmortem Human Brain Tissue Collection,
Characterization
Brain tissue samples were selected from an autopsy case series of
patients evaluated for parkinsonism by movement disorders
specialists at the Movement Disorders Center of Washington
University School of Medicine in St. Louis. The clinical diagnosis
of idiopathic PD was based on modified United Kingdom
Parkinson’s Disease Society Brain Bank clinical diagnostic criteria
with clear clinical response to levodopa [19]. Dementia was
determined by a movement disorders specialist based on clinical
assessment of cognitive dysfunction sufficiently severe to impair
activities of daily living, with further evaluation of cognitive
impairment using the AD8 [20] and Mini-Mental Status Exam
(MMSE) [21]. LB stage was assessed at autopsy using a PD staging
scale (range: 0, 1–6) [4]. PD cases were selected based on a clinical
diagnosis of PD plus dementia, Braak LB stage 5–6 pathology, and
the absence of significant Ab or tau pathology determined by
immunohistochemistry. Control cases were selected based on the
absence of a-syn, Ab and tau pathology. Samples were used from
both male and female subjects.
Mice
Transgenic mouse lines expressing human A53T a-syn (M83
line) or human wild type a-syn (M7 line) were previously
generated in the laboratory of Dr. Virginia M.Y. Lee
(University of Pennsylvania) [22]. Mice used in this study were
homozygous for each of the transgenes and were bred on mixed
B6C3H and 129Sv backgrounds. Mice were housed and cared
for in animal facilities administered through the Washington
University Division of Comparative Medicine. All animal
procedures were performed according to protocols approved
by the Washington University Animal Studies Committee. M83
mice were observed for the development of neurological
impairment and were euthanized after the onset of motor
impairment. Brain tissue was removed and midbrain/pons/
medulla tissue samples were dissected by first making a
midsagittal cut using a brain matrix, which was then followed
by an axial cut at the cervicomedullary junction and a second
axial cut rostral to the superior colliculus for each hemisphere.
Both male and female mice were used in the study.
Radiosynthesis of [125I]SIL23
[125I]SIL23 was radiosynthesized by a halogen exchange
reaction under the catalysis of Cu+ from the corresponding
bromo-substituted precursor (SIL28). Two stock solutions were
prepared for the radiolabelling: Solution A: ascorbic acid
(116 mg) and SnSO4 (6 mg) dissolved in water (1 ml); Solution
B: CuSO4?5H2O (2 mg) and 98% H2SO4 (60 ml) dissolved in
water (2 ml). Both solutions were flushed with helium for
30 min. The precursor (1 mg) was dissolved in DMSO (300 ml)
in a 2 ml reaction vessel containing a stir bar. Solution A
(100 ml) and Solution B (200 ml) were added into the reaction
vessel under nitrogen protection. The reaction vessel was sealed
immediately after the addition of [125I]NaI (3 mCi) and heated
at 130uC for 1 h. After the reaction mixture was cooled to
room temperature, the reaction solution was diluted with 3 ml
mobile phase and injected into a HPLC reverse phase semi-
preparative column (Agilent SB-C18, 5 mm, 106250 mm). The
radioactive product was collected from 30 to 35 min on the
HPLC condition (mobile phase: acetonitrile/water 60/40, v/v;
flow rate: 4 ml/min; UV at 254 nm). The collected fraction was
diluted with 40 ml of water and loaded on a C-18 Sep-Pak
cartridge. After purification by HPLC again, the final product
was eluted by ethanol (1 ml) to form the final solution (1.3 mCi,
radiochemical yield 43%). Since [125I]SIL23 is effectively
separated from the precursor on the semipreparative HPLC
system described above and carrier-free [125I]NaI was used, it is
assumed that the [125I]SIL23 is carrier-free with a theoretical
specific activity of 2200 Ci/mmol [23–25].
Preparation of Recombinant a-syn and Tau Protein
Recombinant protein was produced in E. Coli using protocols
based on previously described methods for a-syn [26–28] and tau
[29]. BL21(DE3)RIL E. Coli were transformed with a pRK172
bacterial expression plasmid containing the human a-syn coding
sequence. Freshly transformed BL21 colonies were inoculated into
2 L baffled flasks containing 250 ml sterilized TB (1.2% bacto-
tryptone, 2.4% yeast extract, 0.4% glycerol, 0.17 M KH2PO4,
0.72 M K2HPO4) with 50 mg/ml ampicillin, and incubated
overnight at 37uC with shaking. Overnight cultures were
centrifuged at 3,9006g for 10 min at 25uC and the bacterial
pellets were resuspended by gentle vortexing in 20 ml osmotic
shock buffer (30 mM Tris-HCl, 2 mM EDTA, 40% Sucrose,
pH 7.2) and then incubated at room temperature for 10 min. The
cell suspension was then centrifuged at 8,0006g for 10 min at
25uC and the pellet was resuspended in 22.5 ml cold H2O before
adding 9.4 ml 2 M MgCl2 to each tube. The suspension was
incubated on ice for 3 min prior to centrifugation at 20,0006g for
15 min at 4uC. After the supernatant was transferred to a fresh
Radioligand for a-Synuclein Fibrils
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tube, streptomycin was added to a final concentration of 10 mg/
ml and centrifuged at 20,0006g for 15 min at 4uC. The
supernatant from this step was collected and dithiothreitol
(DTT) and Tris-HCl pH 8.0 were added to final concentrations
of 1 mM and 20 mM respectively, before boiling for 10 min to
precipitate heat-sensitive proteins, which were pelleted at
20,0006g for 15 min at 4uC. The supernatant was collected and
filtered through a 0.45 mm surfactant-free cellulose acetate filter
(Corning) before loading onto a 1 ml DEAE Sepharose column
equilibrated in 20 mM Tris-HCl pH 8.0, 1 mM EDTA, and
1 mM DTT. The DEAE column was washed with 20 mM Tris-
HCl pH 8.0, 1 mM EDTA, 1 mM DTT before eluting a-syn
protein in 20 mM Tris-HCl pH 8.0 buffer with 1 mM EDTA,
1 mM DTT and 0.3 M NaCl. Purified a-syn protein was dialyzed
overnight in 10 mM Tris-HCl pH 7.6, 50 mM NaCl, 1 mM
DTT. Preparations contained greater than 95% a-syn protein as
determined by sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) and bicinchoninic acid (BCA) protein assay
(Thermo Scientific, Rockford, IL), with a typical yield of 30 mg
protein per 250 ml culture.
Recombinant tau protein was produced in E. Coli.
BL21(DE3)RIL E. Coli were transformed with a pRK172
bacterial expression plasmid encoding a human tau fragment
containing the four microtubule binding repeats (amino acids 243–
375), provided by Marc Diamond at Washington University [30].
Cultures were inoculated and grown overnight as above for a-syn
protein production. Purified tau protein was prepared using a
previously described method [29] and dialyzed overnight in
100 mM sodium acetate pH 7.0.
Preparation of Recombinant a-syn Fibrils
Purified recombinant a-syn monomer (2 mg/ml) was incubated
in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl for 72 h at 37uC with
shaking at 1000 rpm in an Eppendorf Thermomixer. To
determine the concentration of fibrils, the fibril reaction mix was
centrifuged at 15,0006g for 15 min to separate fibrils from
monomer. The concentration of a-syn monomer in the superna-
tant was determined in a BCA protein assay according to the
manufacturer’s instructions, using a bovine serum albumin (BSA)
standard curve. The measured decrease in a-syn monomer
concentration was used to determine the concentration of fibrils
in the 72 h fibril reaction mixture.
Preparation of Ab1–42 Fibrils
Synthetic Ab1–42 peptide (1 mg) (Bachem, Torrance, CA) was
first dissolved in 50 ml DMSO. An additional 925 ml of mQ-H2O
was added. Finally, 25 ml 1M Tris-HCl pH 7.6 was added to bring
the final peptide concentration to 222 mM (1mg/ml) [31]. The
dissolved peptide was incubated for 30 h at 37uC with shaking at
1000 rpm in an Eppendorf Thermomixer. Fibril formation was
confirmed by ThioT fluorescence. To determine the concentration
of fibrils, the fibril reaction mix was centrifuged at 15,0006g for
15 min to separate fibrils from monomer. The concentration of
Ab monomer in the supernatant was determined in a BCA protein
assay using a BSA standard curve that contained DMSO at a
percentage equivalent to the samples.
Preparation of Recombinant Tau Fibrils
Purified recombinant tau monomer (300 mg/ml) was incubated
in 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 25 mM low
molecular weight heparin, 0.5 mM DTT for 48 h at 37uC with
shaking at 1000 rpm in an Eppendorf Thermomixer. To
determine the concentration of fibrils, the fibril reaction mixer
was centrifuged at 15,0006g for 15 min to separate fibrils from
monomer. The concentration of tau monomer in the supernatant
was determined in a BCA protein assay along with a BSA standard
curve. The measured decrease in monomer concentration was
used to determine the concentration of tau fibrils in the 48 h fibril
reaction mixture.
Preparation of a-syn, Ab1–42, and Tau Fibrils for Binding
and Competition Assays
The prepared fibril mixture was centrifuged at 15,0006g for
15 min to prepare fibrils for binding assays. The supernatant was
discarded and the fibril pellet was resuspended in 30 mM Tris-
HCl pH 7.4, 0.1% BSA to achieve the desired concentration of
fibrils for use in the assay.
Preparation of Human Brain Tissue for in vitro Binding
and Competition Studies
Grey matter was isolated from frozen postmortem frontal cortex
tissue by dissection with a scalpel. To prepare insoluble fractions,
dissected tissuewas sequentially homogenized in four buffers (3 ml/g
wet weight of tissue) with glass Dounce tissue grinders (Kimble): 1)
High salt (HS) buffer: 50 mM Tris-HCl pH 7.5, 750 mM NaCl,
5 mMEDTA; 2)HSbufferwith 1%TritonX-100; 3)HSbufferwith
1%TritonX-100 and 1 M sucrose; and 4) phosphate buffered saline
(PBS). Homogenates were centrifuged at 100,0006g after each
homogenization step and the pellet was resuspended and homoge-
nized in the next buffer in the sequence. For comparison in initial
binding studies, crude tissue homogenates were also prepared by
homogenization of tissue in only PBS.
In vitro Saturation Binding Studies of [125I]SIL23
A fixed concentration (1 mM/well) of a-syn, Ab, or tau fibrils
were incubated for 2 h at 37uC with increasing concentrations of
[125I]SIL23 (6.25–600 nM) in 30 mM Tris-HCl pH 7.4, 0.1%
BSA in a reaction volume of 150 ml. A fixed ratio of hot:cold
SIL23 was used for all radioligand concentrations. The exact
hot:cold SIL23 ratio was measured in each experiment by
counting a 10 ml sample of the radioligand preparation in a
scintillation counter. Binding of [125I]SIL23 to human brain
homogenates was assessed by incubating 10 mg samples of
insoluble fraction or 50 mg of crude brain tissue homogenate,
from PD-dementia or control subjects, with increasing concentra-
tions of [125I]SIL23 (6.25–600 nM). Nonspecific binding was
determined in a duplicate set of binding reactions containing the
competitor ThioT. Bound and free radioligand were separated by
vacuum filtration through 0.45 mm PVDF filters in 96-well filter
plates (Millipore), followed by three 200 ml washes with cold assay
buffer. Filters containing the bound ligand were mixed with 150 ml
of Optiphase Supermix scintillation cocktail (PerkinElmer) and
counted immediately. All data points were performed in triplicate.
The dissociation constant (Kd) and the maximal number of
binding sites (Bmax) values were determined by fitting the data to
the equation Y=Bmax*X/(X+Kd) by nonlinear regression using
Graphpad Prism software (version 4.0).
In vitro Competition Studies of [125I]SIL23
Competition assays used a fixed concentration of fibrils (1 mM)
or tissue (10 mg/150 ml reaction) and [125I]SIL23 (200 nM,
consisting of a ratio of 1:400 hot:cold SIL23) and varying
concentration ranges of cold competitor, depending on the ligand.
Competitors were diluted in 30 mM Tris-HCl pH 7.4, 0.1% BSA.
Reactions were incubated at 37uC for 2 h before quantifying
bound radioligand as described above for the saturation binding
assay. All data points were performed in triplicate. Data were
Radioligand for a-Synuclein Fibrils
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analyzed using Graphpad Prism software (version 4.0) to obtain
EC50 values by fitting the data to the equation Y=bottom+(top-
bottom)/(1+10(x-logEC50)). Ki values were calculated from EC50
values using the equation Ki =EC50/(1+[radioligand]/Kd).
Extraction of Insoluble a-syn for Western Blot and ELISA
Insoluble a-syn was isolated by sequential extraction of frozen
postmortem human brain tissue as described previously [32]. Grey
matter was isolated from frozen postmortem frontal cortex tissue
by dissection with a scalpel. To prepare insoluble fractions for
Western blot and ELISA analysis, dissected tissue was sequentially
extracted in six buffers (3 ml/g wet weight of tissue) with glass
Dounce tissue grinders (Kimble) [32]: 1, 2) High salt (HS) buffer:
50 mM Tris-HCl pH 7.5, 750 mM NaCl, 5 mM EDTA; 3) HS
buffer with 1% Triton X-100; 4) HS buffer with 1% Triton X-100
and 1 M sucrose; and 5, 6) 1X radioimmunoprecipitation assay
(RIPA) buffer. Extracts were centrifuged at 100,0006g after each
step and the pellet was resuspended and extracted in the next
buffer in the sequence. The final pellet was then resuspended in
50 mM Tris-HCl pH 8.0, 2% SDS (1 ml/g wet weight of tissue)
and sonicated for 5 sec with 5 sec rest intervals in between for a
total sonication time of 30 sec. Sonicated samples were centrifuged
at 100,0006g and the supernatant was saved (SDS extract). The
pellet was resuspended in 70% formic acid (1 ml/g wet weight of
tissue) and sonicated for 5 sec with 5 sec rest intervals in between
for a total sonication time of 30 sec. The formic acid was
evaporated in a speed vacuum for 2 h. Then 1 volume of 50 mM
Tris-HCl pH 8.0, 2% SDS was added to each sample to solubilize
the protein. The samples were sonicated for 5 sec with 5 sec rest
intervals in between for a total sonication time of 30 sec.
Western Blot
Western Blot was performed as described previously [33].
Frontal cortex PD and control SDS extracts (8 ml) and anterior
cingulate and temporal cortex PD extracts (4 ml) were run on an
18% Tris-glycine gel (Bio-Rad Criterion) and transferred to a
nitrocellulose membrane as described previously [33]. The
membrane was blocked with 5% nonfat milk in Tris buffered
saline (TBS) with 0.1% Tween-20 for 1 h at room temperature,
followed by incubation overnight at 4uC with syn1 (BD
Biosciences) or syn303 [34], both mouse monoclonal antibodies
against a-syn. The blot was then incubated with HRP-conjugated
anti-mouse secondary antibody for 1 h at room temperature,
followed by washing and detection with Immobilon enhanced
chemiluminescence (ECL) reagent (Millipore). The blot was
imaged with the G:Box Chemi XT4 (Synpotics) imager and was
quantified using Multi-Gauge software (Fujifilm). Western blots
included a standard curve of recombinant a-syn protein ranging
from 2.5 ng to 30 ng. The ECL signal was linear over the range of
the standards.
Sandwich ELISA for a-syn
The levels of a-syn were measured by sandwich ELISA
following the sequential extraction procedure. Mouse monoclonal
a-synuclein 211 (Santa Cruz Biotechnology) was used as the
capture antibody and biotinylated goat polyclonal anti-human
synuclein-a (R&D Systems) was used as the detection antibody.
PBS with 0.05%Tween 20, 2% BSA was used to block for 1 h at
37uC before adding samples. All washes were done in PBS-Tween
20. Bound detection antibody was quantified using Streptavidin
Poly HRP80 (Fitzgerald) and SuperSlow 3,39,5,59-Tetramethyl-
benzidine (TMB) liquid substrate (Sigma-Aldrich). The standard
curve was generated by combining bacterial recombinant a-syn
with extracts prepared from control tissue samples, and ranged
from 0 ng/well to 100 ng/well.
Results
[125I]SIL23 Binds to Recombinant a-syn Fibrils
We previously utilized a fluorescent ThioT competition assay
to identify a group of phenothiazine derivatives that bind fibrils
prepared from recombinant a-syn protein (Fig. 1A) [28]. One
of these compounds, (3-iodoallyl)oxy-phenothiazine (SIL23),
displayed moderate affinity for a-syn fibrils (Ki 60 nM) in the
ThioT competition assay, and was suitable for radiolabeling
with 125I. Based on this result, we synthesized [125I]SIL23 to
characterize the binding properties of this novel radioligand in
fibril and tissue assays, and to determine its utility for screening
additional compounds as candidate imaging ligands (Fig. 1B),
which is an essential step in the development of an imaging
agent for PD.
We developed and optimized methods to measure the in vitro
binding affinity of [125I]SIL23 to recombinant a-syn fibrils in
saturation binding experiments. Recombinant a-syn fibrils were
incubated with increasing concentrations of [125I]SIL23. We
determined nonspecific binding in parallel reactions containing
ThioT, unlabeled SIL23, or the phenothiazine analogue SIL5 as
competitors, or in reactions containing radioligand but no fibrils,
all of which yielded similar specific binding values. The binding
data were analyzed by curve fitting using nonlinear regression to
obtain Kd and Bmax values. We observed specific binding of
[125I]SIL23 to a-syn fibrils with a Kd of 148 nM and a Bmax of
5.71 pmol/nmol a-syn monomer (Fig. 2A). We observed consis-
tent binding values for five independently prepared fibril batches
with Kd values ranging from 120 nM to 180 nM. Scatchard
analysis indicates that the binding fits a one-site model (Fig. 2B).
We developed a [125I]SIL23 competitive binding assay to
enable the evaluation of binding affinities for additional pheno-
thiazine analogues. Fixed concentrations of a-syn fibrils and
[125I]SIL23 were incubated with increasing concentrations of each
phenothiazine compound. Four analogues of [125I]SIL23, SIL22
(Fig. 3A), SIL26 (Fig. 3B), SIL3B (Fig. 3C), and SIL5 (Fig. 3D),
were tested and had respective Ki values of 31.9 nM, 15.5 nM,
19.9 nM, and 66.2 nM, all with significantly higher affinities than
the Kd for SIL23, indicating that SIL23 binding assays can guide
the optimization of compound structures to increase binding
affinity for a-syn fibrils.
[125I]SIL23 and Additional SIL Analogues Exhibit Higher
Binding Affinity to Recombinant a-syn Fibrils Compared
to Synthetic Ab1–42 or Recombinant Tau Fibrils
To determine the specificity of [125I]SIL23 for recombinant a-
syn fibrils, we performed in vitro saturation binding studies on
synthetic Ab1–42 (Fig. 4A) and recombinant tau fibrils (Fig. 4B)
and compared the results to data obtained from binding studies
conducted on a-syn fibrils. Overall, the affinity of [125I]SIL23 for
Ab1–42 (Kd 635 nM, Bmax 23.7 pmol/nmol) fibrils was 5-fold
lower than that observed for a-syn fibrils. The affinity for tau fibrils
(Kd 230 nM, Bmax 4.57 pmol/nmol) was approximately 2-fold
lower than a-syn fibrils.
To determine the specificity of other phenothiazine analogues
for a-syn fibrils, we performed radioligand competition assays with
Ab1–42 (Fig. S1A–D) and tau fibrils (Fig. S1E–H) and compared
the obtained Ki values to those obtained in radioligand
competition assays with a-syn fibrils. All of the phenothiazine
analogues examined in this study were selective for a-syn fibrils
over Ab1–42 and tau fibrils, but selectivity varied among analogues
Radioligand for a-Synuclein Fibrils
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(Table 1). SIL26, which has the highest affinity for a-syn fibrils
(Ki 15.5nM), has more than 6-fold lower affinity for Ab1–42 (Ki
103 nM) and more than 7-fold lower affinity for tau fibrils (Ki
125 nM). These results obtained in SIL23 assays with Ab1–42 and
tau fibrils indicate that variations in phenothiazine structure can
enhance selectivity as well as affinity for a-syn fibrils.
[125I]SIL23 Binds to Human PD Brain Homogenates
Previous studies have utilized binding assays with postmortem
human brain homogenates to evaluate candidate amyloid imaging
agents. Development of a similar assay with PD tissue is important
to determine whether a binding site identified on recombinant a-
syn fibrils is also present in PD tissue, and to determine whether
the density of binding sites is high enough to image fibrillar a-syn
in vivo. To evaluate [125I]SIL23 binding to fibrillar a-syn in LBs
and LNs present in PD brain, we compared the in vitro binding of
[125I]SIL23 in postmortem brain tissue from PD and control cases
(Table 2), using insoluble fractions prepared from PD (n= 4) and
control (n = 4) human brain tissue samples. Kd values for the PD
cases ranged from 119 nM to 168 nM (Bmax range 13.3–
25.1 pmol/mg) (Fig. 5A–D). In contrast, we detected no
significant [125I]SIL23 binding in the samples from the control
cases (Fig. 5E–H). These results indicate that [125I]SIL23 binding
affinity in PD brain samples is comparable to the binding affinity
for recombinant a-syn fibrils.
To determine whether SIL23 binding in different PD cases
correlated with total levels of insoluble a-syn, we performed
Figure 1. Phenothiazine structures and radiosynthesis of [125I]SIL23. Structures of SIL23 analogues are shown in A. The radiosynthesis of
[125I]SIL23 is shown in B.
doi:10.1371/journal.pone.0055031.g001
Figure 2. The radioligand [125I]SIL23 binds recombinant a-syn fibrils with a Kd of 148 nM. Fibrils prepared from recombinant a-syn were
incubated with increasing concentrations of [125I]SIL23. Nonspecific binding was determined in parallel reactions utilizing 50 mM ThioT as competitor.
A representative plot of specific binding versus [125I]SIL23 concentration is shown in A. Data points represent mean +/2 s.d. (n = 3). The data was
analyzed by curve fitting to a one-site binding model using nonlinear regression. The Kd value was determined by fitting the data to the equation
Y =Bmax*X/(X+Kd). Scatchard analysis of binding is shown in B. Similar results were obtained in more than three independent experiments.
doi:10.1371/journal.pone.0055031.g002
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western blots on insoluble fractions prepared from PD (n= 6) and
control (n = 4) human brain tissue samples. Western blot results
showed that PD cases had different levels of insoluble a-syn, with
anterior cingulate and temporal cortex PD samples showing the
highest levels (Fig. 6A). In contrast, control cases had very low
levels of detectable a-syn in insoluble fractions, which could
represent low-level carryover of soluble a-syn during sequential
extraction. In addition to monomeric a-syn, higher molecular
weight species, likely representing multimeric a-syn, were also
observed on western blots of insoluble fractions from PD cases
(Fig. 6B). Insignificant levels of a-syn were observed by western
blot analysis of formic acid extracts from the sequential extraction
procedure (see methods).
Total monomeric a-syn present in insoluble SDS fractions
quantified from western blot correlated with Bmax values measured
by the radioligand binding assay (Pearson correlation coefficient
R= 0.99, p = 0.0001) (Fig. 6C). Bmax values also correlated with
insoluble a-syn measured by a sandwich ELISA (Pearson
Figure 3. SIL23 competitive binding assays demonstrate higher affinity binding to recombinant a-syn fibrils for additional
phenothiazine analogues, indicating that the structure of this compound class can be optimized to improve binding affinity using
SIL23 assays. a-Syn fibrils were incubated with 200 nM [125I]SIL23 and increasing concentrations of SIL22 (A), SIL26 (B), SIL3B (C), and SIL5 (D). The
amount of bound radioligand is plotted as a function of the concentration of unlabeled competitor ligand in the incubation mixture. Data points
represent mean +/2 s.d. (n = 3). EC50 values were determined by fitting the data to the equation Y=bottom+(top-bottom)/(1+10(x-logEC50)). Similar
results were obtained in two independent experiments.
doi:10.1371/journal.pone.0055031.g003
Figure 4. Radioligand binding studies demonstrate that [125I]SIL23 has selectivity for binding recombinant a-syn fibrils compared
to synthetic Ab1–42 fibrils or recombinant tau fibrils. Binding affinities of [
125I]SIL23 to Ab (A) and tau (B) fibrils were determined in saturation
binding studies. The determined Kd values of Ab and tau fibrils were 635 nM and 230 nM, respectively. Data points represent mean +/2 s.d. (n = 3).
Similar results were obtained in more than three independent experiments for saturation binding studies.
doi:10.1371/journal.pone.0055031.g004
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correlation coefficient R= 0.98, p = 0.0008) (Fig. S2). The ratios
of Bmax values to insoluble a-syn were approximately 4:1. If
multimeric species were included in the quantification of insoluble
a-syn, the ratios of Bmax values to insoluble a-syn were
approximately 1:1 (Fig. 6D) and were also correlated (Pearson
correlation coefficient R= 0.99, p,0.001). Accuracies of these
ratios may be limited by underestimation of insoluble a-syn due to
low recovery during sequential extraction or incomplete solubili-
zation of fibrils. A ratio of approximately 1 PiB binding site per 2
Ab molecules has been observed in AD brain tissue [11].
In vitro [125I]SIL23 competition assays were used to evaluate the
binding affinity of other SIL analogues with PD brain tissue
samples (Fig. S3A–D). Fixed concentrations of homogenate and
[125I]SIL23 were incubated with increasing concentrations of
unlabeled competitor ligands. The Ki values obtained in assays
with PD brain tissue homogenates were comparable overall to Ki
values obtained with a-syn fibrils but were approximately 2-fold
lower for some ligands (Table 3), indicating that SIL23 binding
assays with recombinant a-syn fibril preparations accurately
predict binding in tissue.
We also used the [125I]SIL23 competition assay to evaluate
other compounds known to bind amyloid fibrils. Fixed concen-
trations of a-syn fibrils and [125I]SIL23 were incubated with
increasing concentrations of PiB, ThioT, BF227, and Chrysamine
G (Table 4, Fig. S4A–D). ThioT displayed a Ki of 1040 nM,
which is comparable to the Kd measured for saturation binding of
ThioT to a-syn fibrils [28]. Ki values for PiB, BF227, and
Chrysamine G were 116 nM, 39.7 nM, and 432 nM respectively.
Additionally, we used the [125I]SIL23 competition assay in PD
tissue homogenates to evaluate the binding properties of these
compounds (Table 4, Fig. S4E–H). We obtained Ki values
comparable to those for recombinant a-syn fibrils, with the
exception of BF227, which displayed weaker competition in PD
tissue assays, possibly corresponding to previous observations that
radiolabeled BF227 binding is not detectable in PD tissue [35].
The Ki values for PiB and BF227 in the competition assays with a-
syn fibrils were significantly higher than Kd values reported for the
binding of radiolabeled PiB and BF227 to a-syn fibrils [13,14,35].
This could reflect differences in a-syn fibril preparations or may
indicate that SIL23 binding sites only partially overlap with these
previously reported ligands.
We further evaluated binding site densities in PD brain using
saturation binding assays with insoluble fractions from other
cortical regions as well as binding assays performed with
unfractionated homogenates of brain tissue samples. Bmax values
for insoluble fractions were significantly higher in temporal cortex
and anterior cingulate cortex compared to frontal cortex
(Table 5). For comparison to a previously reported average Bmax
value of 1407 pmol/g wet weight for PiB binding in AD brain
[11], we estimated Bmax values per gram wet weight for SIL23
binding in PD brain, which ranged from 8% to 63% of PiB values
in AD (Table 5). Saturation binding studies using crude brain
tissue homogenates rather than insoluble protein preparations also
yielded a similar Kd value of 174 nM for a PD case while no
significant binding was observed for a control case (Fig. S5A–D).
The Bmax value for the crude homogenate of a frontal cortex
sample (PD 2) was 16.1 pmol/mg protein, which can be compared
to an average Bmax value of 8.8 pmol/mg protein observed in a
similar assay for AV-45 binding in AD brain [17]. Nonspecific
binding was significantly higher in binding assays with crude
homogenates of brain tissue, possibly due to the high lipophilicity
of SIL23 (calculated log P =5.7). High nonspecific binding,
including nonspecific binding in white matter likely secondary to
lipophilic interactions, also appears to limit autoradiography with
SIL23 in preliminary experiments. Radioligands derived from
other phenothiazine analogues with lower log P values [28] may
overcome this issue.
[125I]SIL23 Binding in a Transgenic Mouse Model for PD
To determine whether SIL23 binding sites are also present in a
transgenic mouse model for PD, we prepared brain tissue
homogenates from transgenic mice expressing either a WT human
a-syn transgene (M7 line) or a human a-syn transgene containing
the A53T mutation that causes hereditary PD (M83 line) [22].
Accumulation of aggregated a-syn occurs primarily in brainstem
and spinal cord of the M83 line but does not occur in the M7 line.
M83 transgenic mice were observed and sacrificed when they
displayed significant neurological impairment, which in this mouse
line corresponds to the presence of aggregated a-syn in brain
tissue. Tissue samples containing the midbrain, pons and medulla
regions were dissected and processed by sequential extraction and
centrifugation to prepare insoluble fractions. In saturation binding
experiments, we observed specific binding of [125I]SIL23 in M83
tissue with a Kd of 151 nM and Bmax of 65.4 pmol/mg (Fig. 7A).
In contrast, we detected no significant [125I]SIL23 binding in M7
mouse brain homogenates (Fig. 7B). The Kd for binding in M83
tissue is similar to that observed for both recombinant a-syn fibrils
and human brain tissue. The Bmax value is comparable to Bmax
values observed for human cortex from PD cases. These results
indicate that this A53T a-syn transgenic mouse model will be
useful for evaluating in vivo binding of candidate a-syn imaging
ligands, using micro-PET imaging or ex vivo autoradiography
following radioligand injection.
Discussion
Our results establish the presence of a [125I]SIL23 binding site
on a-syn fibrils and define the binding properties of SIL23 in PD
brain tissue. SIL23 binds with moderate affinity (Kd 148 nM) to a-
syn fibrils. Furthermore, binding studies demonstrate that the
fibrillar a-syn binding site is present in postmortem brain tissue
from PD but not control cases and that binding site densities in PD
tissue are comparable to binding site densities of Ab imaging
ligands in AD tissue. Competitive binding studies with [125I]SIL23
enable phenothiazine analogues as well as other compounds to be
screened for affinity and selectivity for fibrillar a-syn. This is the
first study to quantify and characterize a radioligand binding site
for a-syn in PD brain tissue. The results demonstrate the feasibility
of targeting a-syn fibrils for in vivo imaging approaches and
establish approaches to identify ligands with suitable binding
Table 1. Comparison of Ki values for SIL analogues in assays
with a-syn, Ab1–42, and tau fibrils illustrates relative selectivity
for a-syn over Ab1–42 and tau.
a-Syn fibrils Ab fibrils Tau fibrils
Competitor Ki (nM) Ki (nM) Ki (nM)
SIL22 31.9 (22.1–45.9) 102 (87.3–119) 173 (144–208)
SIL26 15.5 (11.7–20.6) 103 (83.6–128) 125 (97.7–160)
SIL3B 19.9 (14.9–26.7) 71.5 (54.9–93.2) 52.3 (38.8–70.4)
SIL5 66.2 (49.2–89.1) 110 (94.7–127) 136 (112–165)
Ki values were calculated from EC50 values using the equation Ki = EC50/
(1+[radioligand]/Kd). 95% confidence intervals for Ki values are shown in
parentheses.
doi:10.1371/journal.pone.0055031.t001
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properties for imaging fibrillar a-syn in vivo. They also indicate that
optimization of the structure of phenothiazine analogues could
potentially achieve the desired affinity and selectivity required to
quantify pathological a-syn in vivo.
An imaging tracer that enables quantification of fibrillar a-syn
in vivo would improve the diagnostic accuracy in PD and could be
highly useful as a biomarker for disease progression. Clinical
diagnosis of PD currently relies on the presence of a combination
of bradykinesia, rigidity, rest tremor and postural instability, plus
the absence of additional features indicative of other parkinsonian
disorders. Diagnostic challenges result from the fact that all
features are not present in early PD and that these clinical features
also occur in other disorders including vascular parkinsonism,
MSA, CBD, and PSP. Parkinsonism is also a rare presenting
feature in other neurodegenerative disorders, including fronto-
temporal dementias and AD. Rare hereditary neurodegenerative
disorders can also present with parkinsonism, including syndromes
categorized as hereditary parkinsonism, dystonia-parkinsonism,
spinocerebellar ataxia, and neurodegeneration with brain iron
accumulation. The accuracy of clinical diagnosis of idiopathic PD
ranges from 76% to 92% [19,36,37] and is likely to be lower in
early PD secondary to decreased sensitivity and specificity of the
neurological exam.
A characteristic pattern of fibrillar a-syn deposition in LBs and
LNs distinguishes PD from other disorders and is the defining
feature for pathologic diagnosis. An imaging tracer that quantifies
fibrillar a-syn in vivo would therefore greatly enhance the clinical
diagnosis of PD. Amyloid deposits are absent in vascular
parkinsonism and hereditary disorders such as spinocerebellar
ataxia. Other parkinsonian disorders, including PSP and CBD, are
defined by fibrillar tau accumulation. AD is defined by a
combination of Ab and tau accumulation. MSA, which has
significant potential for phenotypic overlap with PD, is defined by
the presence of fibrillar a-syn, but misfolded a-syn is instead
deposited in glial cytoplasmic inclusions in a brain distribution
pattern that is clearly distinct from PD, based on involvement of
cerebellar and cerebral white matter, pontine nuclei in the basis
pontis, and inferior olivary nuclei in the medulla [38]. This distinct
distribution of pathology for MSA has also been seen in autopsy
cases from patients early in the disease course and in asymptom-
atic individuals [39–41]. Spatial resolution of PET and SPECT
scans may limit the ability to distinguish some brain regions such
as pons and medulla that are differentially affected in PD and
MSA, but resolution should be sufficient to identify MSA-specific
pathology in regions such as cerebellar and cerebral white matter.
Thus, the ability to identify the presence of fibrillar a-syn and to
determine its distribution pattern in the brain could distinguish PD
from most other disorders with overlapping clinical features, with
the exception of rare hereditary disorders such as dystonia-
parkinsonism caused by PLA2G6 mutations [42,43]. Ultimately,
clinical studies that include pathologic confirmation of diagnosis
will be necessary to determine whether an a-syn imaging agent is
useful for the differential diagnosis of parkinsonism. Given the
presence of amyloid fibrils in other neurodegenerative disorders,
in vivo selectivity for a-syn fibrils over tau and Ab fibrils will be
necessary for diagnostic accuracy.
Fibrillar a-syn imaging may also be a highly useful marker for
disease progression. The distribution patterns for pathological a-
syn among autopsy cases with incidental LB disease and
symptomatic PD suggests that disease progression is associated
with an ascending, progressive involvement of multiple brain
regions. A staging system has been proposed [4,44], in which early
stage cases are defined by involvement of olfactory nucleus, as well
as select nuclei in the medulla and pons. Intermediate stages are
defined by additional involvement of substantia nigra pars
compacta, basal forebrain cholinergic nuclei, and select nuclei
within the hypothalamus and amygdala. Late stages are defined by
progressive involvement of neocortex. The link between disease
progression and increasingly widespread involvement of multiple
brain regions is supported by the association of neocortical LBs
with the development of dementia in PD, which occurs in up to
80% of patients within 20 years after onset of motor symptoms [1].
Longitudinal studies with an imaging tracer to quantify the
amount and distribution of fibrillar a-syn in vivo would better
define the natural disease course. This approach could also define
the relative vulnerability of brain regions within the context of
Figure 5. [125I]SIL23 exhibits specific binding to insoluble protein from human PD brain samples but not control human brain
samples. Homogenized insoluble fractions from human brain samples (n = 8) were incubated with increasing concentrations of [125I]SIL23.
Nonspecific binding was determined in parallel reactions utilizing 50 mM ThioT as competitor. Representative plots of specific binding versus
[125I]SIL23 concentration are shown. A–D show four different PD cases and E–H show four control cases. The data was analyzed by curve fitting to a
one-site binding model using nonlinear regression. Kd values for binding to PD-dementia brain samples range from 119.1 nM to 168.3 nM and Bmax
values range from 13–25 pmol/mg insoluble protein. No significant binding of [125I]SIL23 to control samples was observed. Results were verified with
at least two independent experiments.
doi:10.1371/journal.pone.0055031.g005
Table 2. Clinical and demographic information for autopsy cases utilized for binding studies.
Case number Age Gender Clinical Diagnosis Pathologic findings
PD 1 69 M PD, dementia Diffuse Lewy body disease
PD 2 82 F PD, dementia Diffuse Lewy body disease
PD 3 78 M PD, dementia Diffuse Lewy body disease
PD 4 77 M PD, dementia Diffuse Lewy body disease
PD 5 79 M PD, dementia Diffuse Lewy body disease
C1 74 F parkinsonism Arteriosclerosis
C2 78 F parkinsonism, dementia Small vessel infarcts, argyrophilic grain disease
C3 85 M parkinsonism Argyrophilic grain disease, arteriosclerosis
C4 85 M parkinsonism, dementia Small and large vessel disease with neuronal loss
doi:10.1371/journal.pone.0055031.t002
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disease duration and establish correlations between the distribu-
tion of a-syn deposition and non-motor features of PD.
Accurate quantification of fibrillar a-syn in vivo will require a
radiotracer with suitable affinity, selectivity, brain uptake and
metabolism properties. Binding site density in brain is a critical
factor in determining sensitivity and specificity for a radiotracer.
We observe binding site densities of 110–890 pmol/g wet weight,
and 16 pmol/mg protein in binding assays with crude homoge-
nates, for SIL23 binding in human postmortem cortex. These
values are comparable to binding site densities observed for Ab
ligands in AD brain. The average PiB binding site density is
1407 pmol/g wet weight in AD brain [11], and the average AV-
45 binding site density is 8.8 pmol/mg protein in AD brain [17].
Based on Kd values of 2.5 nM for PiB and 3.7 nM for AV-45
binding to Ab plaques, an a-syn binding site density of 16 pmol/
mg protein, and an estimated brain concentration of 1 nM, a
ligand that binds to the SIL23 binding site with a Kd of 7.3 nM
could achieve binding to fibrillar a-syn in PD brain that is
comparable to AV-45 binding in AD. Alternatively, a Kd of
2.5 nM, comparable to the Kd for PiB, will result in binding levels
in cortex ranging from 8% to 63% of PiB levels.
Selectivity requirements for a candidate a-syn imaging ligand
will be dictated by affinity, binding site density, and brain uptake.
The fraction of binding sites occupied at a given ligand
concentration is determined by the Kd based on [ligand]/
([ligand]+Kd). Assuming a brain concentration of 1 nM for an
imaging tracer, selectivity in the range of 10- to 50-fold is desirable
to achieve low binding to Ab and tau fibrils. Selectivity could be
Figure 6. Binding of [125I]SIL23 is correlated with levels of
insoluble a-syn present in PD brain. Levels of a-syn were measured
in insoluble fractions from human brain samples (n = 10) by sequential
extraction and western blot. A representative syn1 western blot with
SDS extracts from PD and control cases is shown in A. A quantitative
syn303 western blot with SDS extracts from PD cases is shown in B, in
which higher molecular weight a-syn species (asterisk) are observed in
combination with monomeric a-syn (arrow). The correlation of Bmax
values for [125I]SIL23 binding to levels of total insoluble a-syn quantified
from the monomer band on western blot is shown in C. The correlation
of Bmax values for [
125I]SIL23 binding to levels of total insoluble a-syn
quantified from monomer plus high molecular weight species on
western blot is shown in D. Results were verified with more than three
independent experiments.
doi:10.1371/journal.pone.0055031.g006
Table 3. Comparison of Ki values for SIL analogues in assays




Competitor Ki (nM) Ki (nM)
SIL22 31.9 (22.1–45.9) 57.1 (44.9–72.6)
SIL26 15.5 (11.7–20.6) 33.5 (26.5–42.3)
SIL3B 19.9 (14.9–26.7) 49.4 (37.6–65.0)
SIL5 66.2 (49.2–89.1) 83.1 (64.3–108)
Ki values were calculated from EC50 values using the equation Ki = EC50/
(1+[radioligand]/Kd). 95% confidence intervals for Ki values are shown in
parentheses.
doi:10.1371/journal.pone.0055031.t003
Table 4. Ki values of previously reported ligands for a-syn
fibrils determined in [125I]SIL23 competitive binding assays




Competitor Ki (nM) Ki (nM)
PIB 116 (88.0–152) 99.2 (72.4–136)
BF227 39.7 (28.1–55.9) 138 (98.7–193)
Chrysamine G 432 (325–573) 367 (275–490)
Thioflavin T 1040 (755–1440) 974 (769–1230)
Ki values were calculated from EC50 values using the equation Ki = EC50/
(1+[radioligand]/Kd). 95% confidence intervals for Ki values are shown in
parentheses.
doi:10.1371/journal.pone.0055031.t004
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further enhanced by the much higher dissociation rate for a
binding site with 10- to 50-fold lower affinity. The relative
densities of a-syn, Ab and tau fibrils in PD and other
neurodegenerative disorders causing parkinsonism is currently
unknown. Our current estimates of selectivity are based on
binding studies utilizing fibrils prepared from recombinant protein
or synthetic peptide.
Evaluation of selectivity could be further improved by developing
tissue binding assays with cases that are clinically relevant to the
diagnosis of PD, including PSP, CBD, and AD. Since SIL23 is only
moderately selective for a-syn fibrils over Ab and tau fibrils, it is
likely to have significant binding in AD, PSP and CBD tissue, and
thus could be utilized in competitive binding assays to determine the
selectivity of unlabeled ligands in tissue assays. However, given the
combination of molecular pathologies often present in AD and
other neurodegenerative disorders, this approach will require
careful selection of cases and quantitative evaluation of a-syn, tau
and Ab pathology in each case. For example, selectivity evaluation
could be enhanced by a panel of cases that includes 1) PD with
dementia containing representative levels of a-syn pathology but no
Ab and tau pathology, 2) AD containing representative levels of Ab
and tau but no a-syn pathology, and 3) PSP/CBD containing only
tau pathology. For high affinity ligands (Kd,10 nM) suitable for
radiolabeling, selectivity could be further evaluated in binding
studies and autoradiography studies at radioligand concentrations
comparable to those likely to be achieved in vivo.
Biomarkers for diagnosis and progression could accelerate the
development of disease-modifying therapies in PD. Early stage PD
may provide the greatest opportunity for effective intervention, yet
accurate diagnosis is challenging. An effective diagnostic maker such
as an a-syn imaging tracer would enable accurate enrollment of
early stage PD patients into trials of therapeutic interventions
targeting disease progression. If progressive accumulation of a-syn
within individual regions or across multiple brain regions correlates
with disease progression, particularly in early and intermediate
disease stages, an a-syn imaging tracer could also greatly improve
evaluation of therapeutic efficacy for candidate disease-modifying
interventions. The development of SIL23 competitive binding
assays is an important step in the development of a radiotracer for
imaging a-syn aggregation in vivo. Since the SIL23 binding site on a-
syn fibrils is a feasible radiotracer target, SIL23 competitive binding
assay can be utilized to screen additional phenothiazine analogues
Table 5. Bmax values determined in saturation binding studies with PD brain tissue samples.
PD case Cortical region Bmax (pmol/mg insoluble protein) Bmax (pmol/g wet weight)
1 midfrontal 14.7 (13.9–15.5) 145
2 midfrontal 19.1 (18.1–20.1) 160
3 midfrontal 13.3 (12.7–13.9) 108
4 midfrontal 25.1 (23.9–26.3) 251
5 temporal 53.1 (45.7–60.5) 607
3 anterior cingulate 91.1 (87.9–94.3) 895
Bmax values are listed for frontal cortex from the four cases shown in Figure 5. Bmax values were significantly higher in temporal cortex and anterior cingulate cortex
samples. In the last column, Bmax values from the same studies are expressed in pmol/g wet weight of brain tissue. 95% confidence intervals for Ki values are shown in
parentheses.
doi:10.1371/journal.pone.0055031.t005
Figure 7. [125I]SIL23 binding sites are present at high density in a transgenic A53T a-syn mouse model for PD. [125I]SIL23 binding was
determined in mouse brain samples obtained from (A) M83 mice with transgenic expression of human A53T a-syn, and (B) M7 mice with transgenic
expression of human WT a-syn. Representative plots of specific binding versus [125I]SIL23 concentration are shown. The data was analyzed by curve
fitting to a one-site binding model using nonlinear regression. [125I]SIL23 binding was detected in M83 brain samples with a Kd of 150.3 nM and a
Bmax of 65 pmol/mg insoluble protein. No significant [
125I]SIL23 binding was detected in M7 brain. The results were verified with two independent
experiments.
doi:10.1371/journal.pone.0055031.g007
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as well as other classes of compounds to identify candidate imaging
ligands with high affinity and selectivity for a-syn. Our results also
demonstrate that SIL23 binding sites are present in a transgenic
mouse model over-expressing A53T a-syn, indicating that brain
uptake and in vivo binding of candidate a-syn imaging ligands can be
evaluated in this mouse model with micro-PET or ex vivo
autoradiography studies.
Supporting Information
Figure S1 Radioligand competition studies demon-
strate that [125I]SIL23 analogues have selectivity for
binding recombinant a-syn fibrils compared to synthetic
Ab1-42 fibrils or recombinant tau fibrils. Competitive
binding studies of Ab and tau fibrils were performed with
increasing concentrations of SIL22 (A, E), SIL26 (B, F), SIL3B (C,
G), and SIL5 (D, H). Data points represent mean +/2 s.d. (n = 3).
Similar results were obtained in more than two independent
experiments. Nonspecific binding varied between individual
experiments based primarily on washing times for individual filter
plates, but the differences between top and bottom values in the
competitive inhibition curves were similar among different
compounds and between different experiments.
(TIF)
Figure S2 Levels of a-syn were measured in insoluble
fractions from human brain samples (n=10) by sequen-
tial extraction and ELISA. A representative plot of the
correlation of Bmax values for [
125I]SIL23 binding to levels of
total insoluble a-syn quantified from ELISA is shown (Pearson
correlation coefficient R= 0.98, p = 0.0008). Results were verified
with more than two independent experiments. Lower levels of a-
syn measured in ELISA may result from low recovery during
sequential extraction or incomplete solubilization of fibrils.
(TIF)
Figure S3 Binding affinities for SIL analogues in human
PD brain samples determined by competitive binding
assays with [125I]SIL23. Homogenized insoluble fractions
from human PD brain samples were incubated with 200 nM
[125I]SIL23 and increasing concentrations of competitor ligands.
Representative plots are shown for competition with SIL22 (A),
SIL26 (B), SIL3B (C), and SIL5 (D). The amount of bound
radioligand is plotted as a function of the concentration of
competitor ligand in the incubation mixture. The results were
verified with two independent experiments.
(TIF)
Figure S4 Binding affinities for previously reported a-
syn ligands determined in [125I]SIL23 competitive
binding assays with recombinant a-syn fibrils and PD
tissue. a-Syn fibrils (A–D) or insoluble fraction from human PD
brain tissue (E–H) were incubated with 200 nM [125I]SIL23 and
increasing concentrations of competitor ligands. Representative
plots are shown for competition with ThioT (A, E), BF227 (B, F),
chrysamine G (C, G), and PiB (D, H). The amount of bound
radioligand is plotted as a function of the concentration of
competitor ligand in the incubation mixture. The results were
verified in two independent experiments.
(TIF)
Figure S5 [125I]SIL23 exhibits similar specific binding
to unfractionated human PD brain homogenates com-
pared to insoluble protein fractions from human PD
brain samples. Crude PBS homogenates from human PD and
control brain samples were incubated with increasing concentra-
tions of [125I]SIL23. Nonspecific binding was determined in
parallel reactions utilizing 50 mM ThioT as competitor. A
representative plot of specific binding versus [125I]SIL23 concen-
tration is shown for PD in A and for control in C. The data were
analyzed by curve fitting to a one-site binding model using
nonlinear regression. The Kd value for binding to PD-dementia
crude brain homogenate was 174 nM, similar to Kd values
obtained from insoluble fractions. The Bmax value for finding to
crude brain homogenate was 16.1 pmol/mg insoluble protein,
which is within the range seen for insoluble fractions. No
significant specific binding was observed for control brain. Results
were verified with at least two independent experiments.
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